The ground breaking results of a 275-patient multi-centered UK clinical trial will be presented at this year’s AUA conference in Boston by Mr. Kasra Saeb-Parsy BSc, MB BS, AFHEA, FRCSEd (Urol), Consultant urologist, Cambridge University Hospitals NHS Foundation Trust
Mr. Saeb-Parsy, one of the PI’s in the study, will be explaining how the MCM assay can achieve a sensitivity of 95.8% and specificity of 91.7% in the gross hematuria clinic and 92.3%/80.3% in the surveillance clinic.
A pioneering new method for the accurate diagnosis of bladder cancer is one step closer thanks to a £½ million funding boost.
The funding from the UK’s innovation agency, Innovate UK, will allow experts at the University of St Andrews to develop technology alongside Aberdeen-based diagnostic specialists Cytosystems.
Cytosystems, a clinical stage diagnostic company, developing new diagnostics for bladder and prostate cancer, and the University of St Andrews have been awarded a grant of £500,000, through the UK’s innovation agency, Innovate UK.
The Award will see Cytosystems and the University of St Andrews develop an automated system for the analysis of cells isolated from urine and which have been attached to a microscope slide. Experts in medical software development, cytopathology and urology will work together to develop software, which automatically analyses the cells, resulting in an extremely accurate test for the presence of bladder cancer. Alongside this, the team will work to create an intuitive software interface for a fully automated workflow from initial analysis to the end result.
Summary of the context and overall objectives of the project
By transforming urine cytology, a complementary adjunct to cystoscopy, Cytosystems is developing technology to reduce the number of cystoscopies required for bladder cancer patients.
Chief Executive, Richard Berry and Director of Product Management, Nigel McLean talk about the Horizon Grant award.
Grant Will Be Used to Accelerate Commercialisation of Bladder Cancer Diagnostic
Aberdeen, 4 May 2016 … Cytosystems, a clinical stage diagnostic company, developing new diagnostics for bladder and prostate cancer, has been awarded a grant of €3.2 million, through the EU Horizon 2020 Scheme, one of the largest grants to be awarded to the life sciences sector of the UK, and the largest for Scotland.
Cytosystems has developed a range of technologies which can be used to improve the diagnosis and management of bladder cancer. The grant will be used to validate specific biomarkers, found in urine, which can be used to accurately detect the presence of cancer.
Scots ideas are widely-acknowledged as providing the building blocks of much of modern medicine. As our latest crop of healthcare technologists head for Medica 2015, what’s behind that history of innovation and how is it shaping up today? If Scottish-born Alexander Fleming hadn't been such an untidy scientist, we would never have the life-saving drugs we have today. His discovery of a mould growing in one of his culture dishes that killed the surrounding bacteria prompted one of the greatest medical breakthroughs of the 20th century.
In celebration of project progress, Cytosystems Ltd have launched a new company website. The new website is accessible at www.cytosystems.com.
The aim of the new website is to better tell our story. We are a non-invasive cancer diagnostics company situated in Aberdeen, whose main vision is to improve the patient experience. We are excited about the progression of our product BladderLightTM and we thought we ought to devote a page explaining why. We have also added a page to pay tribute to all of the organisations who have made Cytosystems Ltd such a success, whether directly or indirectly: http://www.cytosystems.com/index.php/links.
Our website is divided into separate sections depending on your interests:
- For clinicians we explain our scientific development in the Clinical Technology section so you can understand why our technology will benefit healthcare professionals and patients alike.
- For industry please see our product progression in our Products section which explains the potential of our technology.
- For general information about the company you can follow our news feed or visit our publications.
You can also stay in touch by following our LinkedIn page. Overall, we hope that your visit to www.cytosystems.com will be an enjoyable one. If there’s anything else you would like to discuss please contact us – for general enquiries click here, and for partnering enquiries click here.
We thank you for visiting our website and hope to see you again soon.
The Cytosystems Team